Pharming Group Nv Stock Return On Equity

PHAR Stock

USD 7.65 0.12 1.59%

Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Stock. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group stock.

		Last Reported	Projected for Next Year
	Return On Equity	(0.05)	(0.05)

As of 11/26/2024, Return On Equity is likely to drop to -0.05.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pharming Group NV Company Return On Equity Analysis

Pharming Group's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Pharming Group Return On Equity

-0.0818

Most of Pharming Group's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pharming Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Pharming Group is extremely important. It helps to project a fair market value of Pharming Stock properly, considering its historical fundamentals such as Return On Equity. Since Pharming Group's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharming Group's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharming Group's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Good Will	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Property Plant Equipment	Capital Stock	Long Term Investments
Total Assets		0.97	0.19	0.38	0.23	0.7	0.91	0.58	0.97	0.99	0.09	0.81	-0.36	-0.28	0.95	0.68	-0.71	0.92	-0.63	0.84	0.87	0.83	0.79
Total Stockholder Equity	0.97		0.19	0.32	0.42	0.59	0.86	0.6	0.88	0.98	-0.04	0.71	-0.26	-0.17	0.98	0.71	-0.73	0.95	-0.67	0.88	0.91	0.85	0.84
Current Deferred Revenue	0.19	0.19		-0.31	-0.14	0.28	0.26	-0.2	0.18	0.11	0.39	0.41	-0.12	-0.12	0.1	-0.19	0.49	0.08	0.23	-0.08	-0.12	0.12	-0.28
Net Debt	0.38	0.32	-0.31		0.07	0.42	0.57	0.89	0.41	0.41	0.05	0.12	-0.1	-0.11	0.41	0.2	-0.46	0.27	-0.27	0.27	0.55	0.49	0.46
Retained Earnings	0.23	0.42	-0.14	0.07		-0.11	0.13	0.3	0.03	0.3	-0.43	-0.02	0.46	0.57	0.38	0.44	-0.39	0.41	-0.45	0.44	0.44	0.33	0.47
Accounts Payable	0.7	0.59	0.28	0.42	-0.11		0.69	0.47	0.77	0.67	0.2	0.72	-0.26	-0.13	0.55	0.47	-0.25	0.58	-0.39	0.54	0.46	0.56	0.4
Net Receivables	0.91	0.86	0.26	0.57	0.13	0.69		0.68	0.9	0.87	0.37	0.77	-0.37	-0.28	0.87	0.38	-0.59	0.75	-0.33	0.62	0.79	0.71	0.67
Short Term Investments	0.58	0.6	-0.2	0.89	0.3	0.47	0.68		0.52	0.65	-0.17	0.15	-0.09	-0.07	0.68	0.43	-0.63	0.54	-0.48	0.53	0.78	0.73	0.67
Total Liab	0.97	0.88	0.18	0.41	0.03	0.77	0.9	0.52		0.94	0.21	0.87	-0.43	-0.36	0.87	0.61	-0.64	0.83	-0.55	0.76	0.77	0.76	0.7
Total Current Assets	0.99	0.98	0.11	0.41	0.3	0.67	0.87	0.65	0.94		-0.05	0.72	-0.34	-0.26	0.97	0.75	-0.76	0.94	-0.72	0.89	0.91	0.88	0.84
Short Term Debt	0.09	-0.04	0.39	0.05	-0.43	0.2	0.37	-0.17	0.21	-0.05		0.47	-0.27	-0.2	-0.07	-0.59	0.22	-0.19	0.67	-0.35	-0.21	-0.3	-0.27
Intangible Assets	0.81	0.71	0.41	0.12	-0.02	0.72	0.77	0.15	0.87	0.72	0.47		-0.39	-0.29	0.65	0.4	-0.35	0.67	-0.29	0.57	0.48	0.44	0.45
Common Stock	-0.36	-0.26	-0.12	-0.1	0.46	-0.26	-0.37	-0.09	-0.43	-0.34	-0.27	-0.39		0.88	-0.26	-0.12	0.18	-0.24	0.1	-0.2	-0.21	-0.19	-0.19
Good Will	-0.28	-0.17	-0.12	-0.11	0.57	-0.13	-0.28	-0.07	-0.36	-0.26	-0.2	-0.29	0.88		-0.22	-0.11	0.15	-0.21	0.09	-0.17	-0.18	-0.16	-0.16
Net Tangible Assets	0.95	0.98	0.1	0.41	0.38	0.55	0.87	0.68	0.87	0.97	-0.07	0.65	-0.26	-0.22		0.71	-0.8	0.95	-0.67	0.89	0.96	0.85	0.89
Long Term Debt	0.68	0.71	-0.19	0.2	0.44	0.47	0.38	0.43	0.61	0.75	-0.59	0.4	-0.12	-0.11	0.71		-0.68	0.85	-0.97	0.94	0.74	0.72	0.8
Deferred Long Term Liab	-0.71	-0.73	0.49	-0.46	-0.39	-0.25	-0.59	-0.63	-0.64	-0.76	0.22	-0.35	0.18	0.15	-0.8	-0.68		-0.77	0.65	-0.79	-0.87	-0.59	-0.93
Net Invested Capital	0.92	0.95	0.08	0.27	0.41	0.58	0.75	0.54	0.83	0.94	-0.19	0.67	-0.24	-0.21	0.95	0.85	-0.77		-0.77	0.97	0.9	0.78	0.91
Short Long Term Debt	-0.63	-0.67	0.23	-0.27	-0.45	-0.39	-0.33	-0.48	-0.55	-0.72	0.67	-0.29	0.1	0.09	-0.67	-0.97	0.65	-0.77		-0.86	-0.73	-0.78	-0.75
Net Working Capital	0.84	0.88	-0.08	0.27	0.44	0.54	0.62	0.53	0.76	0.89	-0.35	0.57	-0.2	-0.17	0.89	0.94	-0.79	0.97	-0.86		0.88	0.75	0.92
Property Plant Equipment	0.87	0.91	-0.12	0.55	0.44	0.46	0.79	0.78	0.77	0.91	-0.21	0.48	-0.21	-0.18	0.96	0.74	-0.87	0.9	-0.73	0.88		0.83	0.96
Capital Stock	0.83	0.85	0.12	0.49	0.33	0.56	0.71	0.73	0.76	0.88	-0.3	0.44	-0.19	-0.16	0.85	0.72	-0.59	0.78	-0.78	0.75	0.83		0.68
Long Term Investments	0.79	0.84	-0.28	0.46	0.47	0.4	0.67	0.67	0.7	0.84	-0.27	0.45	-0.19	-0.16	0.89	0.8	-0.93	0.91	-0.75	0.92	0.96	0.68

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Pharming Group

Return On Equity Over Time

Pharming Total Stockholder Equity

Total Stockholder Equity

229.72 Million

At this time, Pharming Group's Total Stockholder Equity is relatively stable compared to the past year.

Based on the latest financial disclosure, Pharming Group NV has a Return On Equity of -0.0818. This is 99.66% lower than that of the Biotechnology sector and 99.78% lower than that of the Health Care industry. The return on equity for all United States stocks is 73.61% lower than that of the firm.

Pharming Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.

Pharming Group is currently under evaluation in return on equity category among its peers.

Pharming Group Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pharming Group from analyzing Pharming Group's financial statements. These drivers represent accounts that assess Pharming Group's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pharming Group's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	981.7M	809.3M	497.6M	752.3M	676.7M	710.6M
Enterprise Value	965.6M	766.1M	467.4M	711.7M	792.4M	832.0M

Pharming Group ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pharming Group's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pharming Group's managers, analysts, and investors.

Environmental

Governance

Social

Pharming Fundamentals

	Return On Equity	-0.0818
	Return On Asset	-0.0138
	Profit Margin	(0.06) %
	Operating Margin	0.05 %
	Current Valuation	463.77 M
	Shares Outstanding	67.84 M
	Shares Owned By Institutions	0.10 %
	Number Of Shares Shorted	9.62 K
	Price To Earning	41.53 X
	Price To Book	2.26 X
	Price To Sales	1.79 X
	Revenue	245.32 M
	Gross Profit	188.06 M
	EBITDA	9.88 M
	Net Income	(9.55 M)
	Cash And Equivalents	189.96 M
	Cash Per Share	2.91 X
	Total Debt	171.54 M
	Debt To Equity	0.75 %
	Current Ratio	5.22 X
	Book Value Per Share	0.44 X
	Cash Flow From Operations	(17.3 M)
	Short Ratio	1.32 X
	Earnings Per Share	(0.27) X
	Target Price	33.5
	Number Of Employees	382
	Beta	0.81
	Market Capitalization	510.8 M
	Total Asset	462.85 M
	Retained Earnings	(265.26 M)
	Working Capital	238.37 M
	Net Asset	462.85 M

About Pharming Group Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC